News
Shares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase ...
Researchers at the Chinese Academy of Sciences and collaborators have developed a new method to label and monitor dormant breast cancer cells over time, shedding light on how these cells survive ...
ProKidney Corp. (PROK) shares just saw a massive green day. Results from Phase 2 were compelling and the data sharply ...
US clinical-stage biotech ProKidney reported statistically-significant and clinically-meaningful positive top-line results ...
The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.
ProKidney shares surged 500% on positive Phase 2 CKD results. Read why I remain cautious about PROK stock despite the recent ...
Over the last 7 days, the United States market has remained flat, though it is up 13% over the past year with an optimistic forecast for earnings growth. In such a landscape, identifying stocks with ...
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company ...
12h
Stocktwits on MSNProKidney Stock Skyrockets On Positive Trial Data; Citi Sees 60% Chance Of SuccessShares of ProKidney surged more than 500% on Tuesday following upbeat results from its Phase 2 REGEN-007 study and a price ...
U.S. stocks settled mostly lower on Tuesday, with the Dow Jones index falling more than 150 points during the session ...
ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours ...
A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results